See more : AFC Ajax NV (AFCJF) Income Statement Analysis – Financial Results
Complete financial analysis of Pharma Mar, S.A. (0RC6.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharma Mar, S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- S.R. Accord Ltd. (SRAC.TA) Income Statement Analysis – Financial Results
- Canlan Ice Sports Corp. (CNLFF) Income Statement Analysis – Financial Results
- Hextar Healthcare Berhad (7803.KL) Income Statement Analysis – Financial Results
- Canadian Tire Corporation, Limited (CDNTF) Income Statement Analysis – Financial Results
- Tsukishima Kikai Co., Ltd. (6332.T) Income Statement Analysis – Financial Results
Pharma Mar, S.A. (0RC6.L)
About Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.15M | 196.34M | 229.83M | 269.96M | 85.82M | 162.16M | 179.34M | 180.94M | 192.81M | 148.69M | 140.48M | 138.23M | 152.49M | 153.51M | 123.39M | 105.26M | 85.46M | 76.24M | 471.00K | 669.00K | 80.34M | 65.88M |
| Cost of Revenue | 9.61M | 13.64M | 16.44M | 13.72M | 5.23M | 35.87M | 45.67M | 43.97M | 45.71M | 34.79M | 33.52M | 36.39M | 40.02M | 46.01M | 43.95M | 39.09M | 38.22M | 33.41M | 0.00 | 0.00 | 38.55M | 33.00M |
| Gross Profit | 148.54M | 182.70M | 213.39M | 256.24M | 80.59M | 126.30M | 133.67M | 136.97M | 147.11M | 113.90M | 106.96M | 101.84M | 112.47M | 107.50M | 79.44M | 66.17M | 47.24M | 42.84M | 471.00K | 669.00K | 41.79M | 32.87M |
| Gross Profit Ratio | 93.92% | 93.05% | 92.85% | 94.92% | 93.91% | 77.88% | 74.54% | 75.70% | 76.30% | 76.60% | 76.14% | 73.67% | 73.76% | 70.03% | 64.38% | 62.87% | 55.28% | 56.18% | 100.00% | 100.00% | 52.02% | 49.90% |
| Research & Development | 99.30M | 83.45M | 72.17M | 53.79M | 50.64M | 74.01M | 78.54M | 78.42M | 60.29M | 52.46M | 42.72M | 40.40M | 56.66M | 55.68M | 53.35M | 57.53M | 51.69M | 49.70M | 0.00 | 0.00 | 51.22M | 44.46M |
| General & Administrative | 18.26M | 19.02M | 17.37M | 13.52M | 13.88M | 17.43M | 20.75M | 20.33M | 19.98M | 18.66M | 19.77M | 21.08M | 21.94M | 19.29M | 18.98M | 18.90M | 13.26M | 16.33M | 0.00 | 0.00 | 16.73M | 16.67M |
| Selling & Marketing | 23.54M | 24.22M | 22.37M | 22.26M | 23.94M | 41.82M | 44.76M | 47.69M | 48.61M | 42.17M | 41.25M | 40.87M | 43.47M | 42.84M | 39.39M | 32.24M | 29.28M | 23.37M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.81M | 43.24M | 39.74M | 35.77M | 37.82M | 59.25M | 65.50M | 68.02M | 68.60M | 60.83M | 61.02M | 61.95M | 65.41M | 62.13M | 58.36M | 51.14M | 42.54M | 39.70M | 0.00 | 0.00 | 16.73M | 16.67M |
| Other Expenses | 11.26M | 11.58M | 9.13M | 10.47M | 9.61M | 7.19M | -10.84M | 1.08M | 40.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.24M | 0.00 | 0.00 | 0.00 | -13.89M | -14.70M | 36.00K | 0.00 |
| Operating Expenses | 152.37M | 138.27M | 121.04M | 100.03M | 98.07M | 140.45M | 151.35M | 155.68M | 135.78M | 93.66M | 88.00M | 87.27M | 105.40M | 117.01M | 111.71M | 103.23M | 92.57M | 90.85M | 8.87M | 9.37M | 69.53M | 77.18M |
| Cost & Expenses | 161.98M | 151.91M | 137.48M | 113.75M | 103.29M | 176.31M | 197.02M | 199.65M | 181.49M | 128.45M | 121.52M | 123.66M | 145.42M | 163.03M | 155.66M | 142.32M | 130.79M | 124.25M | 8.87M | 9.37M | 108.08M | 110.18M |
| Interest Income | 4.10M | 875.00K | 370.00K | 336.00K | 35.00K | 69.00K | 102.00K | 193.00K | 180.00K | 513.00K | 752.00K | 932.00K | 852.00K | 746.00K | 167.00K | 753.00K | 0.00 | 0.00 | 0.00 | 3.35M | 0.00 | 0.00 |
| Interest Expense | 2.42M | 2.38M | 3.37M | 3.12M | 3.89M | 4.71M | 5.12M | 5.21M | 5.51M | 6.40M | 6.44M | 6.09M | 6.61M | 5.57M | 5.18M | 6.69M | 0.00 | 0.00 | 0.00 | 1.68M | 0.00 | 0.00 |
| Depreciation & Amortization | 5.76M | 5.90M | 5.58M | 7.21M | 6.06M | 6.38M | 6.61M | 7.21M | 6.28M | 5.26M | 4.59M | 5.91M | 5.82M | 5.33M | 5.28M | 4.58M | 0.00 | 5.87M | 5.64M | 2.33M | 5.36M | 3.36M |
| EBITDA | 4.55M | 52.07M | 104.09M | 155.94M | -11.71M | -9.48M | -12.99M | -12.24M | 14.23M | 26.14M | 24.83M | 21.07M | 13.57M | -3.65M | -15.93M | -36.83M | -40.83M | -42.14M | -33.67M | 293.00K | -22.37M | -40.95M |
| EBITDA Ratio | 2.88% | 27.66% | 45.24% | 57.86% | -13.33% | -4.45% | -5.95% | -6.45% | 9.17% | 17.53% | 17.62% | 15.53% | 9.01% | -2.73% | -21.88% | -30.85% | -53.04% | -55.27% | 1,230.36% | 397.31% | -27.85% | -62.16% |
| Operating Income | -3.83M | 44.07M | 92.45M | 155.94M | -17.48M | -14.07M | -17.68M | -18.71M | 11.33M | 20.24M | 18.96M | 14.57M | 7.07M | -9.52M | -32.27M | -37.06M | -45.33M | -48.01M | -8.40M | -8.70M | -27.74M | -44.31M |
| Operating Income Ratio | -2.42% | 22.45% | 40.22% | 57.77% | -20.36% | -8.68% | -9.86% | -10.34% | 5.88% | 13.61% | 13.49% | 10.54% | 4.63% | -6.20% | -26.15% | -35.20% | -53.04% | -62.97% | -1,782.80% | -1,300.60% | -34.53% | -67.26% |
| Total Other Income/Expenses | 204.00K | -281.00K | -6.36M | -10.34M | -4.17M | -4.04M | -5.17M | -5.99M | -5.39M | -5.76M | -5.16M | -5.14M | -22.71M | -5.03M | 6.05M | -490.00K | -1.66M | -636.00K | -221.00K | 6.66M | -1.29M | 689.00K |
| Income Before Tax | -3.62M | 43.79M | 95.13M | 145.61M | -21.65M | -18.70M | -22.86M | -24.70M | 6.00M | 14.48M | 13.80M | 9.43M | 1.14M | -14.55M | -26.22M | -42.99M | -46.99M | -48.65M | -3.02M | -2.04M | -29.02M | -43.62M |
| Income Before Tax Ratio | -2.29% | 22.30% | 41.39% | 53.94% | -25.23% | -11.53% | -12.75% | -13.65% | 3.11% | 9.74% | 9.82% | 6.82% | 0.75% | -9.48% | -21.25% | -40.84% | -54.99% | -63.81% | -641.40% | -304.93% | -36.13% | -66.21% |
| Income Tax Expense | -4.76M | -5.57M | 2.27M | 8.34M | -12.47M | -2.50M | 3.90M | -592.00K | -654.00K | 1.30M | 1.96M | -5.05M | 2.51M | -2.22M | 1.92M | 746.00K | 3.67M | 0.00 | -3.06M | -3.41M | -2.80M | -8.36M |
| Net Income | 1.14M | 49.36M | 92.86M | 137.26M | -9.18M | -5.54M | -26.75M | -24.08M | 6.59M | 13.12M | 11.32M | 6.59M | -1.37M | -12.33M | -28.14M | -43.74M | -50.67M | -48.65M | 42.00K | 1.37M | -26.22M | -35.26M |
| Net Income Ratio | 0.72% | 25.14% | 40.40% | 50.85% | -10.70% | -3.41% | -14.91% | -13.31% | 3.42% | 8.82% | 8.06% | 4.77% | -0.90% | -8.03% | -22.80% | -41.55% | -59.29% | -63.81% | 8.92% | 204.63% | -32.64% | -53.52% |
| EPS | 0.06 | 2.73 | 5.14 | 7.50 | -0.50 | -0.30 | -1.45 | -1.31 | 0.36 | 0.72 | 0.60 | -2.28 | -0.07 | -0.67 | -1.54 | -2.45 | -2.82 | -2.75 | -2.28 | 0.08 | -1.57 | -2.11 |
| EPS Diluted | 0.06 | 2.73 | 5.13 | 7.49 | -0.50 | -0.30 | -1.45 | -1.31 | 0.36 | 0.72 | 0.60 | -2.28 | -0.07 | -0.67 | -1.54 | -2.45 | -2.82 | -2.74 | -2.28 | 0.08 | -1.57 | -2.11 |
| Weighted Avg Shares Out | 17.90M | 18.05M | 18.07M | 18.29M | 18.44M | 18.41M | 18.39M | 18.38M | 18.38M | 18.32M | 18.36M | 18.40M | 18.38M | 18.35M | 18.25M | 17.83M | 17.97M | 17.72M | 16.97M | 17.62M | 16.73M | 16.73M |
| Weighted Avg Shares Out (Dil) | 17.92M | 18.06M | 18.09M | 18.33M | 18.44M | 18.41M | 18.43M | 18.42M | 18.44M | 18.39M | 18.42M | 18.46M | 18.48M | 18.45M | 18.31M | 17.83M | 17.97M | 17.76M | 16.97M | 17.62M | 16.73M | 16.73M |
Source: https://incomestatements.info
Category: Stock Reports